ICU Medical, Inc. Provides Updated Unaudited Earnings Guidance for the Year 2024
May 07, 2024 at 04:05 pm EDT
Share
ICU Medical, Inc. provided updated unaudited earnings guidance for the year 2024. For the year, the company expected GAAP net loss to be $127 million to $110 million. GAAP diluted loss per share to be $5.16 to $4.46.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
ICU MEDICAL, INC. 
